Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
recovery

Spotlight: Smart Recovery & Psychedelic-Assisted Psychotherapy

On Psychedelics in Recovery
Michael DeMarco, PhD

by Michael DeMarco, PhD

Dr. Michael DeMarco is a licensed mental health and family therapist and has pursued additional training in the use of psychedelic medicines for those struggling with substance use disorders. He emphasizes that there has been a significant amount of research about the use of Ketamine and other medications over the course of decades, and it's important to know how to put such research in an appropriate context.

SmartRecovery Podcast: Psychedelic Assisted Therapy: Research and Practice

See Also:

Post by @PsychedelicInstitute@mastodon.social
View on Mastodon

Post by @PsychedelicInstitute@mastodon.social
View on Mastodon

More like this

Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)

"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)

"enhancing baseline dopamine while minimising excessive drug-induced dopamine surges may help normalise motivational circuits and reduce relapse risk."

Spotlight: From Anesthetic to Neuroprotector: Multi-Omics Reveals Ketamine's Previously Unexplored Neuroprotective Role in Alzheimer's Disease (Gong, et al, 2025)

"This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted."

Spotlight: Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)

"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."

Spotlight: Brain changes associated with depression treatment: a meta-analysis

Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.

Spotlight: NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review (Badrfam, et al, 2025)

"Ketamine infusions have improved processing speed and verbal learning in bipolar disorder patients. Evidence suggests that NMDA receptor-modulating agents play a significant role in improving cognitive function in patients with bipolar disorder. "
Mastodon Mastodon